clairop

IBS vs IBD: Key Differences, Red Flags and Tests

IBS is a gut-brain disorder; IBD (Crohn's and ulcerative colitis) is chronic inflammation. How symptoms overlap, which tests separate them and which red flags matter.

Clairop Team22 min read

Photo: The Ridge Ohio / Unsplash

The short answer

IBS is a disorder of gut-brain interaction with no visible inflammation; IBD, meaning Crohn's disease and ulcerative colitis, is chronic bowel inflammation that can damage tissue. Symptoms overlap, so doctors use stool calprotectin, blood tests such as CRP, colonoscopy and sometimes imaging. Visible blood, weight loss, anemia, fever and night-time symptoms point away from IBS and need a doctor promptly.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

IBS and IBD sound alike and can feel alike, but they are different conditions. IBS (irritable bowel syndrome) is a disorder of gut-brain interaction: the gut is sensitive and its movement is disturbed, but there is no inflammation or tissue damage that standard tests can find. IBD (inflammatory bowel disease) is the umbrella term for Crohn's disease and ulcerative colitis, where the immune system drives chronic inflammation that can cause ulcers, bleeding, narrowing of the bowel and other complications. Because both can cause pain, diarrhea and urgency, telling them apart takes tests, not guesswork.

This guide is for anyone who has been told "it's probably IBS" and wonders about IBD, or who has IBD and is still having symptoms that do not seem to match their scope results. It sets out how the two differ, what the numbers say about each test, and which warning signs deserve a prompt appointment. It cannot tell you which one you have. Only a clinician with your results can do that.

What is the difference between IBS and IBD?

IBS is a disorder of gut-brain interaction, meaning the bowel's sensitivity and movement are disturbed without an inflammatory lesion that tests can detect, whereas IBD is chronic immune-driven inflammation of the gut. That difference in mechanism explains why one is diagnosed largely from a symptom pattern and the other needs evidence of inflammation. If you are wondering whether it is too late to develop Crohn's, see can you be diagnosed with Crohn's after 30 or 40?. For how IBS is diagnosed without a scope, see can IBS be diagnosed without a colonoscopy? and is IBS a real diagnosis?.

The British Society of Gastroenterology reclassified IBS as a disorder of gut-brain interaction in its 2021 guideline, rather than a purely "functional" condition (Vasant 2021). The American College of Gastroenterology guideline recommends a positive diagnostic strategy, meaning that doctors identify IBS from its symptom pattern with limited testing rather than only by excluding everything else (Lacy 2021). The Rome IV criteria, the symptom framework used for that, require recurrent abdominal pain on average at least one day a week over the last three months that is linked to bowel movements and a change in how often or how loose the stool is, with symptoms starting at least six months earlier (Mearin 2016). You can see how your own answers line up with it in the Rome IV IBS criteria checker, though a result there is not a diagnosis.

IBD is defined differently. Ulcerative colitis is inflammation that starts in the rectum and can extend continuously to the rest of the colon, usually presenting with bloody diarrhea and diagnosed by colonoscopy and biopsy (Ungaro 2017). Crohn's disease typically appears as a young person with abdominal pain, chronic diarrhea, weight loss and fatigue (Torres 2017). In Crohn's, skip lesions (patches of disease separated by healthy bowel), involvement of the ileum and granulomas on biopsy all point towards the diagnosis (Lamb 2019).

IBS vs IBD at a glance

IBSUlcerative colitisCrohn's disease
What it isDisorder of gut-brain interactionChronic inflammation of the colon, starting in the rectumChronic inflammation that can involve the ileum and colon, often in patches
Typical patternPain linked to bowel movements, with a change in stool frequency or formBloody diarrhea, urgencyAbdominal pain, chronic diarrhea, weight loss, fatigue
Stool calprotectinUsually lowUsually raised when activeUsually raised when the colon is involved; less reliable evidence for small bowel disease
CRPUsually normalOften normal or only modestly raised despite active diseaseOften raised when active
ColonoscopyNormal-looking bowelContinuous inflammation from the rectumPatchy inflammation, ulcers, often ileum involved
Can cause complications such as strictures, fistulas or need for surgeryNoColectomy in some casesStrictures, penetrating disease and surgery in some cases

Can IBS turn into IBD?

IBS does not physically transform into IBD, but people diagnosed with IBS are later diagnosed with IBD more often than you would expect, and the likeliest explanation is that early IBD was mistaken for IBS. The honest summary is that the research cannot yet separate "IBS leads to IBD" from "IBD was there all along".

The largest relevant dataset is a US military cohort of 9,341 people with a new IBS diagnosis matched to 18,678 people without. Those with IBS had an 8.6-fold higher incidence of IBD afterwards (238.1 versus 27.8 per 100,000 person-years), rising to a 15-fold higher risk in a subset with a well-defined IBS diagnosis, and the median time between the two diagnoses was 2.1 years. A gut infection also roughly doubled the risk of IBD after allowing for IBS. The authors themselves say the findings reflect a complex interaction between how illness presents and how it is diagnosed, and that it is unknown whether IBS lies on the causal pathway to IBD or the two sit on a spectrum of the same illness (Porter 2012).

A short gap of about two years is typical of an early diagnosis revised, not of a slow biological conversion. Primary care data point the same way. In a UK study of 19,555 people with IBD, one in four had reported gut symptoms to their primary care doctor (GP in the UK) more than six months before diagnosis, and a previous IBS diagnosis was associated with delays in specialist review (Blackwell 2021).

Delay is not harmless. A systematic review of 101 studies found that the median time from symptom onset to diagnosis was 8.0 months in Crohn's disease and 3.7 months in ulcerative colitis, and that delayed diagnosis was associated with higher odds of strictures (OR 1.88), penetrating disease (OR 1.64) and intestinal surgery (OR 2.24) in Crohn's. In UC, delayed diagnosis was linked to colectomy, though that estimate is very imprecise (OR 4.13, 95% CI 1.04 to 16.40) (Jayasooriya 2023). Association is not proof of cause here, but it is a reason to push for answers if something does not fit.

If you were diagnosed with IBS and your symptoms change, for example new blood, weight loss, night-time diarrhea or a result that is raised, ask your doctor whether IBD should be checked. See a doctor promptly for any of those. Our guide to what can be mistaken for ulcerative colitis covers the diagnostic errors in the other direction.

Crohn's vs IBS symptoms: how do they differ?

Crohn's disease and IBS share abdominal pain, diarrhea and fatigue, but Crohn's is more likely to bring weight loss, symptoms at night, blood or mucus, perianal problems and anemia, and it leaves measurable traces in stool and on scans. None of these features is certain on its own.

The classic Crohn's picture is a young person with abdominal pain, chronic diarrhea, weight loss and fatigue (Torres 2017). Because Crohn's can be patchy and involve the ileum, pain is often felt in the lower right abdomen, whereas IBS pain is typically tied to bowel movements and often eases after a movement. Pain tied to eating, with weight loss, can reflect narrowing of the bowel, which IBS does not cause.

The overlaps are why this is hard:

  • Pain. Both can cause cramping. In IBS the pain is linked to defecation, a change in stool frequency, or a change in stool form (Mearin 2016).
  • Diarrhea. Both. In Crohn's it tends to be chronic and may come with blood, mucus or night-time waking; in IBS-D it often has a post-meal or morning pattern, but this is not reliable enough to separate them.
  • Fatigue. Both can cause it. Fatigue was independently associated with IBS in people whose IBD was in remission, so tiredness alone does not distinguish anything (Olsen 2025).
  • Constipation. IBS-C is common. Crohn's can also cause constipation, for example with narrowed bowel, so constipation does not exclude it.

One study of people who met Rome III IBS criteria and had a colonoscopy is a useful reality check. Among 136 people with no alarm features at all, Crohn's disease was the most common organic finding (7.4%), ahead of celiac disease (2.9%) and microscopic colitis (2.2%) (Patel 2015). That group was selected, since all had been sent for colonoscopy, so it does not mean that one in 14 people with IBS has Crohn's. It does show that "no red flags" is reassuring, not a guarantee.

Our post on a normal colonoscopy with ongoing symptoms goes into what to do when the scope is clear.

How does ulcerative colitis differ from IBS?

Ulcerative colitis is a disease of the colon that starts in the rectum, and its hallmark is bloody diarrhea. IBS can cause urgency and mucus but is not expected to cause visible blood, and UC shows continuous inflammation on colonoscopy where IBS shows a normal-looking bowel.

UC typically presents with bloody diarrhea and is diagnosed by colonoscopy and histology (Ungaro 2017). That is the clearest symptom-level difference between UC and IBS. If you are passing blood, do not file it under IBS. Hemorrhoids can also bleed, but the two can coexist, so blood still needs to be assessed. See a doctor promptly.

Other features that tend to separate the two:

  • Blood. Visible blood mixed in with stool or on the surface, especially with urgency and frequent loose stools, is a UC pattern and not part of IBS.
  • Night. Waking to open the bowels is a classic reason to look for inflammation.
  • Inflammation markers. CRP often rises less in UC than in Crohn's. A review of CRP in IBD notes that UC has only a modest to absent CRP response despite active inflammation (Vermeire 2004). A normal CRP therefore does not exclude UC, which is why calprotectin and endoscopy matter.
  • Infection first. In suspected UC, the UK BSG guideline says stool cultures and a C. difficile toxin assay should always be done to rule out infective causes (Lamb 2019).

If you have been told you have UC in remission but still have symptoms, that situation is common and has its own explanations; see UC symptoms in remission.

What tests tell IBS and IBD apart?

The usual sequence is blood tests including CRP, a stool calprotectin, stool tests to exclude infection, then colonoscopy with biopsies if the picture or markers suggest IBD, with MRI, ultrasound, CT or capsule endoscopy to look at the small bowel when Crohn's is suspected. No single test is both perfect and easy.

Fecal calprotectin

Calprotectin is a protein released by white blood cells, and stool levels rise when there is inflammation in the bowel. It is the central non-invasive test for this question.

  • In a systematic review for the UK health technology program, calprotectin at a cut-off of 50 micrograms per gram distinguished IBD from IBS in adults with a pooled sensitivity of 93% and specificity of 94%. Sensitivities in individual studies ranged from 83% to 100%, and specificities from 60% to 100%. The review flagged results between 50 and 150 micrograms per gram as an area of uncertainty, noting most such people do not have IBD, and that repeat testing may be reasonable before referral (Waugh 2013).
  • An earlier meta-analysis in adults found a sensitivity of 0.93 and specificity of 0.96, and estimated a 67% reduction in the number of adults needing endoscopy. Three of 33 adults who still had endoscopy turned out not to have IBD (van Rheenen 2010).
  • In people with IBS symptoms, a calprotectin of 40 micrograms per gram or below, or a CRP of 0.5 or below, gave 1% or less probability of IBD. Importantly, the same analysis found none of these markers reliably separated IBS from healthy people (Menees 2015). A normal calprotectin is a way to make IBD unlikely, not a test that confirms IBS.
  • The ACG guideline suggests checking fecal calprotectin in people with suspected IBS and diarrhea to rule out IBD (Lacy 2021).

The detail that matters in practice is how to read a result. For a raised number without symptoms, see high calprotectin but no symptoms, and for timing, see how long calprotectin results take. You can also paste a result into the calprotectin result explainer.

Blood tests (CRP and others)

CRP is made in the liver in response to inflammation. In Crohn's it correlates well with disease activity, but in ulcerative colitis the response is often modest or absent despite active inflammation (Vermeire 2004). A normal CRP is mildly reassuring in someone with IBS symptoms and a CRP of 0.5 or below contributed to the very low IBD probability above (Menees 2015), but it is the weaker of the two markers and can be normal in active IBD. A blood count for anemia is also standard, since anemia is a red flag.

Colonoscopy and biopsies

Colonoscopy with biopsies is the reference test. For suspected Crohn's, the BSG guideline recommends a full ileocolonoscopy, and for suspected UC a full ileocolonoscopy to confirm the diagnosis and extent, usually within the first year. It lists skip lesions, ileal involvement and granulomatous inflammation as more suggestive of Crohn's, and continuous inflammation from the rectum as the UC pattern (Lamb 2019). A normal scope with normal biopsies is strong evidence against inflammation in the parts of the bowel reached, which is why it can support an IBS diagnosis.

Imaging and capsule endoscopy

The colonoscope reaches the colon and the last stretch of ileum, but not the rest of the small bowel. The BSG guideline says dedicated small bowel imaging should complement ileocolonoscopy in all adults with suspected Crohn's. In a cohort of 150 people with Crohn's, 36 had active small bowel disease found on CT enterography after a normal ileocolonoscopy. MR enterography and small bowel ultrasound are preferred because they avoid ionizing radiation, and meta-analyzes show sensitivity and specificity in the region of 85% to 95% for Crohn's. Capsule endoscopy can be used where small bowel inflammation is still suspected despite normal or equivocal imaging (Lamb 2019).

Which test for which question?

QuestionReasonable first testWhat a normal result means
Is there inflammation in the bowel at all?Stool calprotectin, CRPIBD is unlikely, not impossible
Is it an infection?Stool culture, C. difficile testInfection less likely
Is it UC or Crohn's colitis?Colonoscopy with biopsiesRules out inflammation in the colon reached
Is there small bowel Crohn's?MR enterography, ultrasound, CT, capsuleLowers likelihood in the segments imaged
Is it IBS?Symptom criteria plus limited testsSupports IBS; it is a positive diagnosis, not just exclusion

Can you have IBS and IBD at the same time?

Yes. Many people with IBD in remission report symptoms that meet IBS criteria, and the numbers are large enough that it is a recognized overlap, not a rarity. The first job when it happens is to confirm inflammation really is quiet.

A meta-analysis of 27 studies covering 3,169 people with IBD in remission found a pooled prevalence of IBS-type symptoms of 32.5%. It was lower when remission was confirmed by endoscopy (23.5%) or histology (25.8%) than when defined by clinical activity scores (33.6%), and higher in Crohn's disease (36.6%) than in UC (28.7%). Anxiety and depression scores were higher in those with IBS-type symptoms (Fairbrass 2020).

A Norwegian cohort using Rome IV and objective remission found a similar picture. Among people with fecal calprotectin of 250 micrograms per gram or below, IBS-type symptoms were present in 21.9% at one year and 16.1% at three years, roughly twice the 9.5% in the general Norwegian population. At one year, 19.2% of those in endoscopic remission reported them as well. The symptoms were independently associated with substantial fatigue (OR 3.05) and female sex (OR 2.67) (Olsen 2025).

Why does this matter?

  • Symptoms are a poor proxy for inflammation. In a study of 356 people with UC or Crohn's, patient-reported symptoms had poor positive predictive value for mucosal inflammation, and the Harvey-Bradshaw index was a poor predictor of inflammation in Crohn's. Symptom reporting was associated with psychological factors such as somatization (Gracie 2016). That is not a statement that symptoms are "in your head". It means gut sensitivity and inflammation are separate drivers that can each cause symptoms.
  • Wrongly escalating treatment can miss the point. The BSG guideline notes that when response to treatment is poor, clinicians should check that the diagnosis is right, and that proximal constipation and co-existing IBS can contribute to symptoms and poor response. It also suggests IBS-style dietary advice for people with functional symptoms in remission or mildly active disease (Lamb 2019).
  • The reverse also holds. Do not assume that every flare of symptoms is "just IBS" in someone with IBD. Ask for calprotectin or other objective checks, and see a doctor promptly if you have blood, weight loss, fever or night-time symptoms.

Any change to IBD medication belongs to your gastroenterology team. Nothing here is a reason to stop or alter treatment on your own.

If you are trying to work out which pattern you have, dated detail helps the conversation. Clairop logs stool form, blood, mucus, urgency and night-time episodes in a tap, and its one-page GI visit report puts that record in front of your doctor, labeled as patient-entered data. It is iPhone only, free to download, and not a diagnostic tool; see how it works.

Download on the App Store

Which red flags point away from IBS?

Visible blood in the stool, unexplained weight loss, fever, waking at night to open your bowels, anemia, symptoms starting after about 50 and a family history of bowel cancer or IBD are commonly used red flags. They do not prove anything, but they are reasons to see a doctor promptly and not settle on IBS.

The evidence on red flags is more nuanced than the checklists suggest, and it is worth knowing both sides.

  • They are imperfect individually. In a chart review of 1,434 people with a clinical diagnosis of IBS, abdominal pain, diarrhea or constipation, red flags were reported by 84% of people, yet the positive predictive value of an individual red flag for organic disease was only 7% to 9%. IBD was found in 1.2% of people diagnosed with IBS and gastrointestinal cancer in 1.0%. The authors concluded that red flags are useful for identifying people who need more evaluation, but that excluding everyone with one would leave most people with no diagnosis (Whitehead 2006).
  • They do change the odds. In 559 people meeting Rome III IBS criteria at colonoscopy, organic disease was found in 27.7% of those with at least one alarm feature and 15.4% of those with none (Patel 2015).
  • Their absence is not a guarantee. The same study found Crohn's in 7.4% of the group with no alarm features.

What this means practically: a red flag is a prompt to investigate, not a diagnosis, and a lack of red flags does not close the question if symptoms persist or change. Specifically:

  • Visible blood. Needs assessment. Do not assume hemorrhoids without a check.
  • Weight loss you did not intend. Needs assessment.
  • Waking at night with diarrhea or pain. Needs assessment.
  • Fever, anemia or raised inflammatory markers. Needs assessment.
  • New symptoms after 50. Needs assessment, partly because bowel cancer is on the list of things to exclude.
  • A close relative with IBD or bowel cancer. Mention it, as it changes the threshold for testing.

If any of these apply, see a doctor promptly. If you have severe pain, heavy bleeding, a high fever or feel faint, seek urgent care.

What do people in the community ask about IBS and IBD?

The same questions come up again and again in patient communities. In r/ibs, threads such as "What was diagnosed as IBS but turned out to be something else?" and "I was diagnosed with IBS turns out it wasn't IBS" draw hundreds of replies, and another asks "Anyone here with IBS and later diagnosed with IBD?". In r/CrohnsDisease, people ask whether a normal calprotectin can coexist with a diagnosis of IBD and what to make of a normal calprotectin alongside several red flag symptoms.

These threads show what worries people, not what is medically true. A recurring theme is the fear of being told "it's only IBS" when something feels different, and the opposite fear of going through investigations only to be told everything is normal. The research above supports both concerns: delay in diagnosing IBD is real and costly, and many people with IBS-type symptoms are found to have no inflammation. The way through is objective testing matched to your symptoms.

Myths about IBS and IBD

"IBS is just a milder IBD." No. They are different conditions with different mechanisms, and severity is not the dividing line. IBS can be profoundly disruptive without any inflammation, and IBD can be quiet.

"A normal colonoscopy means it cannot be Crohn's." Not entirely. Colonoscopy does not see the whole small bowel, and small bowel imaging found active disease in 36 of 150 Crohn's patients after a normal ileocolonoscopy in the evidence cited by the BSG guideline (Lamb 2019).

"A normal calprotectin rules IBD out." It makes it unlikely. Sensitivity ranged from 83% to 100% in individual studies (Waugh 2013).

"If I have IBD I cannot also have IBS." You can. About a quarter to a third of people with IBD in remission report IBS-type symptoms (Fairbrass 2020).

"IBS is a diagnosis of exclusion that needs every test." Guidelines favor a positive diagnosis from the symptom pattern, with limited tests such as calprotectin where diarrhea is prominent, not an endless search (Lacy 2021).

"If it's not IBD, it's all in my head." Disorders of gut-brain interaction are real conditions with recognized treatments, and the BSG guideline exists to guide that care (Vasant 2021).

How do you prepare for an appointment about IBS or IBD?

A short, dated record often makes the difference between a vague conversation and a useful one. Useful things to bring:

  1. The start date and pattern. When it began, and whether it is constant or comes in episodes.
  2. Blood, mucus and night-time episodes. Doctors weigh these heavily, so record them as they happen rather than from memory.
  3. Weight and appetite changes.
  4. Family history. IBD, bowel cancer or celiac disease in relatives.
  5. Recent antibiotics, infections, travel and anti-inflammatory painkillers. These can raise calprotectin or cause diarrhea.
  6. Past results. Previous calprotectin, CRP, blood counts and scope reports.

Questions to ask: What do my results say about inflammation? Is a scope or small bowel imaging needed? How would we know if this changed? Would a repeat calprotectin help? A food and symptom log can also show whether a pattern is tied to meals, which is useful for IBS but is not a way to diagnose IBD.

When should you see a doctor about IBS or IBD symptoms?

See a doctor promptly if you notice blood in your stool, unexplained weight loss, a fever, symptoms that wake you at night, signs of anemia such as unusual tiredness or breathlessness, symptoms starting after 50, or a family history of IBD or bowel cancer. See a doctor too if you have been told you have IBS and your symptoms change, or if you have IBD and symptoms return. For severe pain, heavy bleeding, a high fever or fainting, seek urgent care.

What the evidence cannot tell you

Most of the data above comes from secondary-care or selected populations, which can overstate how often serious disease is found. The red flag studies used older Rome criteria (II and III), and calprotectin cut-offs vary by assay and population. The IBS-after-IBS and IBD-after-IBS figures come from observational data and cannot settle cause and effect. Clairop is not a medical device and cannot tell you whether you have IBS or IBD; only a clinician with your results can.

Frequently asked questions

What is the difference between IBS and IBD?
IBS is a disorder of gut-brain interaction: the bowel misbehaves without the inflammation or tissue damage that tests can find. IBD, which means Crohn's disease and ulcerative colitis, is chronic inflammation of the gut that can cause ulcers, bleeding, strictures and complications. The symptoms overlap, so stool calprotectin, blood tests and often colonoscopy are used to tell them apart.
Can IBS turn into IBD?
There is no good evidence that IBS physically transforms into IBD. In one large US military cohort, people diagnosed with IBS were later diagnosed with IBD at a much higher rate, a median of about 2.1 years afterwards, which most plausibly reflects early IBD labeled as IBS first. If symptoms change or red flags appear, ask for IBD to be checked.
Can you have IBS and IBD at the same time?
Yes. A meta-analysis found about one in three people with IBD in remission reported IBS-type symptoms, falling to about one in four when remission was confirmed by endoscopy or biopsy. Doctors usually first check that inflammation is truly quiet with calprotectin or a scope, because ongoing inflammation and IBS-type symptoms feel alike.
Is Crohn's disease just a worse form of IBS?
No. They are different conditions with different mechanisms. Crohn's disease is chronic inflammation that can occur anywhere along the gut, often in patches, and can lead to strictures and fistulas. IBS involves no such tissue damage. Severity is not the dividing line: IBS can be severely disabling, and Crohn's can be mild, so the tests matter.
What tests tell IBS and IBD apart?
The usual first steps are a stool calprotectin and blood tests including CRP. A very low calprotectin makes IBD unlikely in someone with IBS-type symptoms. If results are raised or symptoms are worrying, colonoscopy with biopsies is the reference test, sometimes with MRI, CT, ultrasound or capsule endoscopy to look at the small bowel.
Can a normal calprotectin rule out Crohn's disease?
It makes IBD much less likely but does not remove all doubt. In a health technology review, calprotectin picked up IBD in 93% of cases at a cut-off of 50 micrograms per gram, with individual studies ranging from 83% to 100%. If blood, weight loss or persistent symptoms continue despite a normal result, tell your doctor.
Which symptoms suggest IBD rather than IBS?
Red flags include visible blood in the stool, unexplained weight loss, fever, waking at night with diarrhea, anemia, symptoms starting after 50 and a family history of IBD or bowel cancer. Individual red flags are imperfect, but they justify further tests. See a doctor promptly if you have any of them rather than assuming it is IBS.
Does IBD cause constipation like IBS can?
It can. Diarrhea is more typical, but constipation occurs in IBD too, for example with narrowed bowel, inflamed rectum or proximal constipation, and IBS-C is common as well. Constipation does not rule IBD in or out. What separates them is blood, inflammation markers, weight loss, anemia and what testing shows.
What's the best way to track symptoms to tell IBS from IBD?
Clairop gives you one-tap Bristol stool entries with blood, mucus, urgency and night-time detail, so the features doctors weigh most are dated and easy to show. It is iPhone only, patient-entered and not diagnostic. Bring the log to your appointment, alongside any family history and the date symptoms began.
What's the best test to tell IBS from ulcerative colitis?
For ulcerative colitis the decisive test is colonoscopy or sigmoidoscopy with biopsies, since UC starts in the rectum and runs continuously upward. Stool calprotectin is the best non-invasive first step, and stool cultures with a C. difficile test exclude infection. CRP is often normal in UC, so a normal CRP does not exclude it.
Is it IBS if my colonoscopy was normal?
Possibly, but a normal colonoscopy does not exclude everything. A colonoscopy can miss small bowel Crohn's disease, and in one series of 150 people with Crohn's, 36 had active small bowel disease on CT enterography after a normal ileocolonoscopy. Further imaging is reasonable if symptoms and markers suggest it.

Sources

  1. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40. doi:10.1136/gutjnl-2021-324598
  2. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036
  3. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407. doi:10.1053/j.gastro.2016.02.031
  4. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484
  5. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-55. doi:10.1016/S0140-6736(16)31711-1
  6. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-70. doi:10.1016/S0140-6736(16)32126-2
  7. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-54. doi:10.1038/ajg.2015.6
  8. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17(55):xv-xix, 1-211. doi:10.3310/hta17550
  9. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369. doi:10.1136/bmj.c3369
  10. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):661-5. doi:10.1097/00054725-200409000-00026
  11. Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053-62. doi:10.1016/S2468-1253(20)30300-9
  12. Olsen BC, Opheim R, Kristensen VA, Hoivik ML, Lund C, Aabrekk TB, et al. Prevalence of irritable bowel syndrome based on Rome IV criteria in patients in biochemical and endoscopic remission from newly diagnosed inflammatory bowel disease: one- and three-year results (the IBSEN III cohort). Inflamm Bowel Dis. 2025;31(10):2704-13. doi:10.1093/ibd/izaf047
  13. Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol. 2016;111(4):541-51. doi:10.1038/ajg.2016.59
  14. Porter CK, Cash BD, Pimentel M, Akinseye A, Riddle MS. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol. 2012;12:55. doi:10.1186/1471-230X-12-55
  15. Whitehead WE, Palsson OS, Feld AD, Levy RL, Von Korff M, Turner MJ, et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther. 2006;24(1):137-46. doi:10.1111/j.1365-2036.2006.02956.x
  16. Patel P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P, et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol. 2015;50(7):816-23. doi:10.3109/00365521.2015.1007079
  17. Blackwell J, Saxena S, Jayasooriya N, Bottle A, Petersen I, Hotopf M, et al. Prevalence and duration of gastrointestinal symptoms before diagnosis of inflammatory bowel disease and predictors of timely specialist review: a population-based study. J Crohns Colitis. 2021;15(2):203-11. doi:10.1093/ecco-jcc/jjaa146
  18. Jayasooriya N, Baillie S, Blackwell J, Bottle A, Petersen I, Creese H, et al. Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):635-52. doi:10.1111/apt.17370

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools